A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Phase I trial
inotuzumab ozogamicin
non-Hodgkin lymphomas
temsirolimus
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
20
8
2021
medline:
18
3
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
This phase I trial evaluated the safety, tolerability, and preliminary activity of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed/refractory CD22 positive B-cell non-Hodgkin lymphomas. Nineteen patients received at least one dose of both study drugs. Dose-limiting toxicities consisted of thrombocytopenia, hypertriglyceridemia, oral mucositis, clinical deterioration, and the inability to receive at least three doses of temsirolimus during cycle 1. The most common grade ≥3 treatment-related adverse events were thrombocytopenia (
Identifiants
pubmed: 34407735
doi: 10.1080/10428194.2021.1966780
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
CD22 protein, human
0
Sialic Acid Binding Ig-like Lectin 2
0
temsirolimus
624KN6GM2T
Inotuzumab Ozogamicin
P93RUU11P7
Sirolimus
W36ZG6FT64
Banques de données
ClinicalTrials.gov
['NCT01535989']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM